Share This Article:

Mast Cell Infiltration and Leukotriene Receptor Expression in Various Tumors: Possible Clinical Application of Common Pathological Findings Concerned with Tumor Development

Abstract Full-Text HTML XML Download Download as PDF (Size:644KB) PP. 606-612
DOI: 10.4236/jct.2015.67066    2,720 Downloads   3,098 Views   Citations

ABSTRACT

Since the mechanisms of the developmental processes of tumors remain unclear, early detection and early treatment of the tumors is necessary to save patients with malignant tumors. Therapies currently available to patients are surgery, chemotherapy, and radiotherapy. However, there are many patients who cannot be saved by such therapies. In this study, we found the common features of various tumor tissues, and we demonstrated the effect of therapeutics that target them by using experimental rats with spontaneous tumors. 26 kinds of human tumors (epithelial or mesenchymal origin, and malignant or benign) and Sprague-Dawley rats with spontaneous mammary gland tumors were examined by light and electron microscope. To detect of mast cells and leukotriene receptor, toluidine blue stain and immunohistochemical stain were performed. The rats were orally administered one of leukotriene receptor antagonists. We found that the presence of numerous mast cells and expression of leukotriene receptors in various tumor (human tumors and rat spontaneous tumors). And the therapeutic effects, which suppressed not only tumor progress but also angiogenesis and nerve formation, for rat tumors by administration of leukotriene receptor antagonist could obtain. Our data suggest the possibility that allergic reactions, in which leukotriene and leukotriene receptors in particular appear to play an important role, are involved in the development and progression of tumors and that it may be possible to control tumor progression by regulating such reactions. Our results might be useful for clinical applications of oncotherapy.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Sugamata, M. , Ihara, T. and Sugamata, M. (2015) Mast Cell Infiltration and Leukotriene Receptor Expression in Various Tumors: Possible Clinical Application of Common Pathological Findings Concerned with Tumor Development. Journal of Cancer Therapy, 6, 606-612. doi: 10.4236/jct.2015.67066.

References

[1] Uchiide, I., Ihara, T. and Sugamata, M. (2002) Pathological Evaluation of the Rat Endometriosis Model. Fertility and Sterility, 78, 782-786.
http://dx.doi.org/10.1016/S0015-0282(02)03327-7
[2] Sugamata, M., Ihara, T. and Uchiide, I. (2005) Increase of Activated Mast Cells in Human Endometriosis. American Journal of Reproductive Immunology, 53, 120-125.
http://dx.doi.org/10.1111/j.1600-0897.2005.00254.x
[3] Ihara, T., Uchiide, I. and Sugamata, M. (2004) Light and Electron Microscopic Evaluation of Antileukotriene Therapy for Experimental Rat Endometriosis. Fertility and Sterility, 81, 819-823.
http://dx.doi.org/10.1016/j.fertnstert.2003.08.029
[4] Ihara, T., Uchiide, I. and Sugamata, M. (2004) Light and Electron Microscopic Evaluation of Antileukotriene Therapy on Human Endometriosis. In: Daya, S., Pierson, R., Gundy, J., Eds., International Congress Series, Vol. 1271, Research Papers in Fertility and Reproductive Medicine, Elsevier BV, Amsterdam, 221-224.
http://dx.doi.org/10.1016/j.ics.2004.05.165
[5] Ihara, T., Yamamoto, T., Sugamata, M., Okumura, H. and Ueno, Y. (1998) The Process of Ultrastructural Changes from Nuclei to Apoptotic Body. Virchows Archiv, 433, 443-447.
http://dx.doi.org/10.1007/s004280050272
[6] Sugamata, M., Ihara, T. and Uchiide, I. (2015) A New Therapy for Human Endometriosis: The Therapeutic Value of Leukotriene Receptor Antagonist for Endometriosis. Open Journal of Obstetrics and Gynecology, 5, 313-318.
http://dx.doi.org/10.4236/ojog.2015.56045

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.